Evidence map›Paper›PMID 42060649›Full record

ArticlePloS one2026

Interpretable multivariate survival models: Improving predictions for conversion from mild cognitive impairment to Alzheimer's disease via data fusion and machine learning.

Diana Sofia Rosales-Gurmendi, Gerardo Alejandro Fumagal-González, Jorge Orozco, Joshua Farber, Victor Treviño, Emmanuel Martinez-Ledesma, Antonio Martinez-Torteya, Fabiola Rosales-Gurmendi, Jose Tamez-Peña, Alzheimer’s Disease Neuroimaging Initiative

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Diana Sofia Rosales-GurmendiSchool of Engineering and Sciences, Tecnologico de Monterrey, Monterrey, Mexico.
Gerardo Alejandro Fumagal-GonzálezSchool of Engineering and Sciences, Tecnologico de Monterrey, Monterrey, Mexico.ORCID https://orcid.org/0009-0008-2041-8056
Jorge OrozcoSchool of Engineering and Sciences, Tecnologico de Monterrey, Monterrey, Mexico.ORCID https://orcid.org/0000-0002-7196-3977
Joshua FarberQmetrics Technologies LLC, Rochester, New York, United States of America.
Victor TreviñoSchool of Medicine and Health Sciences, Tecnologico de Monterrey, Monterrey, Mexico.
Emmanuel Martinez-LedesmaSchool of Medicine and Health Sciences, Tecnologico de Monterrey, Monterrey, Mexico.
Antonio Martinez-TorteyaEngineering Department, Universidad de Monterrey, Monterrey, Mexico.
Fabiola Rosales-GurmendiSchool of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru.
Jose Tamez-PeñaSchool of Medicine and Health Sciences, Tecnologico de Monterrey, Monterrey, Mexico.
Alzheimer’s Disease Neuroimaging Initiative

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurately predicting which individuals with mild cognitive impairment (MCI) will progress to Alzheimer's disease (AD) can improve patient care. This study examines the role of quantitative MRI (qMRI), cognitive evaluations, apolipoprotein [Formula: see text]4 (APOE [Formula: see text]4), and cerebrospinal fluid (CSF) biomarkers in Cox survival models to predict progression from MCI to AD. Data from 564 participants in the ADNI study, who transitioned from MCI to AD, were analyzed. The data set included 330 features encompassing qMRI, cognitive assessments, CSF biomarkers, and APOE [Formula: see text]4 status. Advanced machine learning (ML) methods were applied to evaluate the importance of these data sources, select relevant features, and develop interpretable Cox survival models within a cross-validation framework. The top optimized model achieved a sensitivity of 0.69, 95% CI [0.63, 0.76], and a specificity of 0.87, 95% CI [0.83, 0.90], and used all data sources. The results demonstrated that combining qMRI features with cognitive assessments, CSF biomarkers, and APOE [Formula: see text]4 status, analyzed using the BSWiMS model, resulted in a substantial improvement in the ability to predict progression from MCI to AD, achieving 81% precision and 87% specificity. These results exceed those obtained with other models evaluated. Finally, biomarker analysis showed that cognitive scores are the most relevant features to predict conversion, followed by CSF and qMRI biomarkers. These findings highlight the value of integrating multiple data sources in highly interpretable Cox survival models for the early identification of individuals at risk for AD.

Indexed as

Alzheimer DiseaseCognitive DysfunctionMachine LearningAgedAged, 80 and overBiomarkersDisease ProgressionFemaleHumansMagnetic Resonance ImagingMalePrediction AlgorithmsPredictive Learning ModelsProportional Hazards ModelsBiomarkers

Identifiers

PMID42060649
PMCPMC13132236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.